Combined approach with biologics and surgery for enterocutaneous fistulas in Crohn's disease.
Fries
Walter
W
La Malfa
Giuseppe
G
Costantino
Giuseppe
G
Repici
Alessandro
A
Mazziotti
Silvio
S
Navarra
Giuseppe
G
D000068879:Adalimumab; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D003131:Combined Modality Therapy; D003424:Crohn Disease / Q000150:complications*; D017577:Cutaneous Fistula / Q000188:drug therapy* / Q000209:etiology / Q000601:surgery*; D005260:Female; D006801:Humans; D000069285:Infliximab; D007412:Intestinal Fistula / Q000188:drug therapy* / Q000209:etiology / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors; D055815:Young Adult
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D000068879:Adalimumab